Efficacy evaluation of the Melissa officinalis syrup in treatment of children's anxiety symptoms with Attention Deficit Hyperactivity Disorder

Phase 2

Recruiting

• Conditions: Attention Deficit Hyperactivity Disorder.; Attention-deficit hyperactivity disorder, predominantly inattentive type; F90.0

• Registration Number: IRCT20221001056065N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

The patient with DSM V ADHD criteria,
Absence of other systemic or psychiatric disorders,
IQ in the normal range
at least three months have passed since their standard drug treatment,
Completion of the informed consent form by the parent

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Revised Children's Anxiety Scale. Timepoint: in 3 and 6 weeks. Method of measurement: The amount of change in the revised children's anxiety scale questionnaire.;Attention deficit hyperactivity disorder scoring scale questionnaires. Timepoint: in 3 and 6 weeks. Method of measurement: The amount of change in attention deficit hyperactivity disorder scoring scale.

Secondary Outcome Measures

Name	Time	Method
Revised Children's Manifest Anxiety Scale score. Timepoint: week 3 and 6. Method of measurement: The amount of change in the anxiety score.